- Home
- RILY vs PLRX Comparison
RILY vs PLRX Comparison
Compare RILY & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RILY
- PLRX
- Stock Information
- Founded
- RILY 1973
- PLRX 2015
- Country
- RILY United States
- PLRX United States
- Employees
- RILY N/A
- PLRX N/A
- Industry
- RILY Investment Managers
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- RILY Finance
- PLRX Health Care
- Exchange
- RILY Nasdaq
- PLRX Nasdaq
- Market Cap
- RILY 88.4M
- PLRX 90.9M
- IPO Year
- RILY 2007
- PLRX 2020
- Fundamental
- Price
- RILY $2.82
- PLRX $1.46
- Analyst Decision
- RILY
- PLRX Hold
- Analyst Count
- RILY 0
- PLRX 10
- Target Price
- RILY N/A
- PLRX $9.79
- AVG Volume (30 Days)
- RILY 654.2K
- PLRX 744.6K
- Earning Date
- RILY 05-20-2025
- PLRX 05-20-2025
- Dividend Yield
- RILY 17.73%
- PLRX N/A
- EPS Growth
- RILY N/A
- PLRX N/A
- EPS
- RILY N/A
- PLRX N/A
- Revenue
- RILY $854,383,000.00
- PLRX N/A
- Revenue This Year
- RILY N/A
- PLRX N/A
- Revenue Next Year
- RILY N/A
- PLRX N/A
- P/E Ratio
- RILY N/A
- PLRX N/A
- Revenue Growth
- RILY N/A
- PLRX N/A
- 52 Week Low
- RILY $2.67
- PLRX $1.10
- 52 Week High
- RILY $37.08
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- RILY 36.58
- PLRX 41.55
- Support Level
- RILY $2.80
- PLRX $1.43
- Resistance Level
- RILY $3.10
- PLRX $1.72
- Average True Range (ATR)
- RILY 0.19
- PLRX 0.11
- MACD
- RILY 0.03
- PLRX 0.05
- Stochastic Oscillator
- RILY 11.30
- PLRX 27.78
About RILY B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.